Sponsor
Xijing Hospital
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Xijing Hospital appears in 104 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownSafety and Efficacy of S103 Cells in Progressive/Refractory Multiple SclerosisNCT07587125 · lead sponsor · 2026-05-08
RECRUITINGPlasma Exosomal RNA Signature for Prostate Cancer Bone MetastasisNCT07553754 · lead sponsor · 2026-03-12
RECRUITINGA Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate CancerNCT07474142 · lead sponsor · 2026-03-03
RECRUITINGStudy on the Cosmetic Outcome and Safety Evaluation of 3D Printed Biodegradable Biological Mesh for One-Stage Breast Reconstruction After Radical MastectomyNCT07365267 · lead sponsor · 2026-01-15
RECRUITINGA Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBCNCT07178171 · lead sponsor · 2025-11-06
RECRUITINGA Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With SurgeryNCT07071402 · lead sponsor · 2025-07-18
RECRUITINGEffect of a Pharmacist-led Multifaceted Intervention on Treatment Outcomes in Hypertensive PatientsNCT06558877 · lead sponsor · 2025-06-20
RECRUITINGNeoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast CancerNCT06914440 · lead sponsor · 2025-06-05
RECRUITING3D-printed Biodegradable Breast Implants for Breast RestorationNCT06993714 · lead sponsor · 2025-05-01
RECRUITINGClinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled TrialNCT06938360 · lead sponsor · 2025-02-20
RECRUITINGAdvantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）NCT06669182 · lead sponsor · 2025-01-07
RECRUITINGAssessment and Management of Multiple Drug Use in Elderly Chronic Disease PatientsNCT07180368 · lead sponsor · 2024-10-01
RECRUITINGNeoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate CancerNCT06575257 · lead sponsor · 2024-05-01
RECRUITINGResearch on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast CancerNCT07012720 · lead sponsor · 2024-04-01
RECRUITINGResearching the Useful of Barb Suture in Obese Patients Undergoing Posterior Cervical SurgeryNCT05895968 · lead sponsor · 2023-01-01
RECRUITINGPlasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate CancerNCT07492927 · lead sponsor · 2021-03-12
RECRUITINGSerial PSMA PET for Therapy Monitoring in Clinically Significant Prostate CancerNCT07553780 · lead sponsor · 2021-03-07
RECRUITINGDelayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate CancerNCT07531329 · lead sponsor · 2021-03-05
RECRUITINGExtended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast CancerNCT07532096 · lead sponsor · 2026-04-25
NOT_YET_RECRUITINGSerplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast CancerNCT07466303 · lead sponsor · 2026-03-25
NOT_YET_RECRUITINGExemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast CancerNCT07498400 · lead sponsor · 2026-01-01
ACTIVE_NOT_RECRUITINGCarvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic VaricesNCT07352228 · lead sponsor · 2026-01-01
ENROLLING_BY_INVITATIONNeratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerNCT07333937 · lead sponsor · 2025-12-20
NOT_YET_RECRUITINGSacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBCNCT07007780 · lead sponsor · 2025-08-20
NOT_YET_RECRUITINGAβ PET and Tau PET Imaging in the Diagnosis and Progression Assessment of Alzheimer's DiseaseNCT07114224 · lead sponsor · 2025-08-15
NOT_YET_RECRUITINGLong-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and DiabetesNCT07082933 · lead sponsor · 2025-08-01
NOT_YET_RECRUITINGImpact of Sevoflurane Versus Propofol on Postoperative Delirium in Elderly Diabetic Patients Undergoing Non-Cardiac Surgery: a Multicenter, Randomized Controlled TrialNCT06788743 · lead sponsor · 2025-06-01
COMPLETEDEfficacy and Mechanism of Transcranial Temporal Interference Stimulation (tTIS) in the Treatment of Adolescent DepressionNCT06902064 · lead sponsor · 2025-03-31
NOT_YET_RECRUITINGPET/CT Imaging Study With Simultaneous Dual-nuclide Imaging TechniqueNCT06914427 · lead sponsor · 2025-03-28
NOT_YET_RECRUITINGZoledronic Acid Combined With EC-T for Triple-Negative Breast CancerNCT06876636 · lead sponsor · 2025-03-10
ACTIVE_NOT_RECRUITINGStudy on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor MicroenvironmentNCT06762925 · lead sponsor · 2025-01-30
NOT_YET_RECRUITINGA Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast CancerNCT06769919 · lead sponsor · 2024-12-31
NOT_YET_RECRUITINGCerebellar ITBS Mode Transcranial Magnetic Stimulation for the Treatment of Alzheimer's DiseaseNCT06379100 · lead sponsor · 2024-04-20
COMPLETEDNeuronavigation Guided iTBS With Personalized Target for DepressionNCT05577481 · lead sponsor · 2023-07-10
COMPLETEDA Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast CancerNCT07162051 · lead sponsor · 2023-03-03
COMPLETEDIndividualized dlPFC-NAcc Modulation for Anhedonia in adMDDNCT05544071 · lead sponsor · 2023-02-12
COMPLETEDAnlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast CancerNCT05558722 · lead sponsor · 2022-12-05
ACTIVE_NOT_RECRUITINGNeoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast CancerNCT05444998 · lead sponsor · 2022-11-01
COMPLETEDClinical Study of 68Ga Labeled HER2 Affibody AnaloguesNCT05411432 · lead sponsor · 2022-06-01
UNKNOWNA Clinical Study on the Effect of Hypoglycemic Drugs on the Prognosis of Spinal Surgery in Diabetic PatientsNCT05214235 · lead sponsor · 2022-02-07
UNKNOWNRC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast CancerNCT05134519 · lead sponsor · 2021-11-26
UNKNOWNHypertension, Antihypertensive Medication Use, and Risk of PsoriasisNCT06075394 · lead sponsor · 2021-11-01
COMPLETEDA Comparative Study on the Efficacy of Different Stepping-down Therapy for Childhood AsthmaNCT04953741 · lead sponsor · 2021-08-01
UNKNOWN68Ga-PSMA PET in the Prostate CancerNCT04967001 · lead sponsor · 2021-06-01
UNKNOWNComparison of Safety and Patients-Reported Outcomes Between Single-Port Endoscopic and Conventional Nipple-Sparing Mastectomy With Immediate Implant ReconstructionNCT07410728 · lead sponsor · 2021-04-21
COMPLETEDFirst in Man Study of Implantable Alginate HydrogelNCT04781660 · lead sponsor · 2021-04-01
UNKNOWNPlasma Exosome RNA to Diagnose Prostate CancerNCT06604130 · lead sponsor · 2021-03-12
ENROLLING_BY_INVITATIONOptimized Cardioprotection Therapy in Obese Subjects With AMINCT04570514 · lead sponsor · 2020-10-01
UNKNOWNPLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast CancerNCT05346107 · lead sponsor · 2020-01-01
UNKNOWNDetection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum DeviceNCT04239105 · lead sponsor · 2020-01-01
UNKNOWNPIONEER Trial:Hemodynamic Support With ECMO and IABP in Elective Complex High-risk PCINCT04045873 · lead sponsor · 2019-12-01
UNKNOWNNab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast CancerNCT04182568 · lead sponsor · 2019-08-21
UNKNOWNSentinel Lymph Node Biopsy in Early Breast Cancer: a Real-world Multicenter Cross-sectional Study (CABS001 Study)NCT04156841 · lead sponsor · 2019-08-01
UNKNOWNClinical Study of Escitalopram Oxalate Combined With taVNS in Depression and Concomitant Inflammatory SymptomsNCT04037111 · lead sponsor · 2019-07-23
UNKNOWNBreast Cancer Treatment Based on Organ-like CultureNCT03925233 · lead sponsor · 2019-01-02
UNKNOWNOptimized Cardioprotection Therapy in Obese Subjects With CADNCT04570527 · lead sponsor · 2019-01-01
UNKNOWNRecurrence Risk Evaluation by 21-gene DetectionNCT03841266 · lead sponsor · 2019-01-01
COMPLETEDStudy for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes MellitusNCT03829891 · lead sponsor · 2018-08-07
COMPLETEDTranscatheter Aortic Valve Replacement With Extracorporeal Life System SupportNCT04160624 · lead sponsor · 2018-08-01
UNKNOWNSafety Study of 3D Printing Personalized Biodegradable Implant for Breast ReconstructionNCT03348293 · lead sponsor · 2018-07-30
COMPLETEDDrugs studied in this sponsor's trials
35 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Xijing Hospital as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
cyclophosphamide3
paclitaxel2
anastrozole1
bevacizumab1
capecitabine1
carboplatin1
carvedilol1
cisplatin1
cyclophosphamide RxCUI 3002 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting
3 trials
paclitaxel RxCUI 56946 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
anastrozole RxCUI 84857 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
capecitabine RxCUI 194000 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
carboplatin RxCUI 40048 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
carvedilol RxCUI 20352 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
cisplatin RxCUI 2555 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
darolutamide RxCUI 2180325 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
doxorubicin hydrochloride RxCUI 142433 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
epirubicin RxCUI 3995 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
epirubicin hydrochloride RxCUI 203213 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
eribulin mesylate RxCUI 1045452 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
exemestane RxCUI 258494 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
exenatide RxCUI 60548 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
fluorouracil RxCUI 4492 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
fulvestrant RxCUI 282357 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
gemcitabine RxCUI 12574 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
goserelin 3.6 MG RxCUI 358339 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
ixabepilone RxCUI 337523 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
lapatinib RxCUI 480167 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
letrozole RxCUI 72965 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
methotrexate RxCUI 6851 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
olaparib RxCUI 1597582 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
Sponsor roles
lead sponsor89
collaborator15
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.